IPP Bureau
Colgate joins hands with Haryana to bring oral health education to 5.7 million school children
By IPP Bureau - February 24, 2026
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
By IPP Bureau - February 24, 2026
Under the deal, Quiver will receive an undisclosed advance payment and research support
AbbVie to invest $380 million in new North Chicago manufacturing facilities
By IPP Bureau - February 24, 2026
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Bayer introduces chemo-free treatment option for advanced prostate cancer in India
By IPP Bureau - February 24, 2026
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
By IPP Bureau - February 24, 2026
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
By IPP Bureau - February 24, 2026
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
biomodal expands multiomic reach with Element Biosciences pact
By IPP Bureau - February 24, 2026
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Sai Life Sciences to hire 700+ professionals to support expansion
By IPP Bureau - February 24, 2026
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
By IPP Bureau - February 24, 2026
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
By IPP Bureau - February 24, 2026
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction
By IPP Bureau - February 24, 2026
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy
By IPP Bureau - February 24, 2026
If approved, DTX401 would be the first treatment to address the disease at its root cause
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
By IPP Bureau - February 24, 2026
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks
By IPP Bureau - February 24, 2026
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion
By IPP Bureau - February 23, 2026
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
